Reviewing Onconova Therapeutics (ONTX) and ChemoCentryx (CCXI)
Onconova Therapeutics (NASDAQ: ONTX) and ChemoCentryx (NASDAQ:CCXI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.
Volatility & Risk
Onconova Therapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.
Earnings and Valuation
This table compares Onconova Therapeutics and ChemoCentryx’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Onconova Therapeutics||$2.36 million||7.22||-$22.15 million||($2.35)||-0.74|
|ChemoCentryx||$26.31 million||13.35||-$30.76 million||($0.62)||-11.63|
Onconova Therapeutics has higher revenue, but lower earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations and price targets for Onconova Therapeutics and ChemoCentryx, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Onconova Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 362.43%. Given Onconova Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Onconova Therapeutics is more favorable than ChemoCentryx.
Insider & Institutional Ownership
26.8% of Onconova Therapeutics shares are held by institutional investors. Comparatively, 50.1% of ChemoCentryx shares are held by institutional investors. 27.3% of Onconova Therapeutics shares are held by insiders. Comparatively, 26.8% of ChemoCentryx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Onconova Therapeutics and ChemoCentryx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
ChemoCentryx beats Onconova Therapeutics on 8 of the 13 factors compared between the two stocks.
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
Receive News & Stock Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related stocks with our FREE daily email newsletter.